TIMI Risk Score for Secondary Prevention (TRS 2P) Calculator

Clinical calculation support · Verify results before clinical use

Risk factor assessment

Select each clinical factor present. Each factor contributes one point.

0Score
1

Age ≥75 years

Age at the time of assessment is 75 years or older.

+1 point
2

History of congestive heart failure

A documented history of congestive heart failure.

+1 point
3

Hypertension

A documented diagnosis or history of hypertension.

+1 point
4

Diabetes mellitus

A documented diagnosis of diabetes mellitus.

+1 point
5

Prior stroke

A history of stroke (not isolated transient ischemic attack unless classified as stroke in the source record).

+1 point
6

Prior coronary artery bypass grafting (CABG)

A history of coronary artery bypass graft surgery.

+1 point
7

Peripheral arterial disease (PAD)

A documented history of peripheral arterial disease.

+1 point
8

Renal dysfunction

A documented history of renal dysfunction (use the definition applied in the source clinical record).

+1 point
9

Current smoking

Currently smokes tobacco at the time of assessment.

+1 point
0TRS 2P
Risk category
Low risk
0 risk indicators.

The score summarizes the number of established clinical risk indicators. Interpret it in the context of the patient's clinical status and overall secondary-prevention assessment.

About the TRS 2P

The TIMI Risk Score for Secondary Prevention (TRS 2P; also written TRS 2°P) is a 0–9 point clinical risk score developed to stratify the risk of subsequent atherothrombotic events in patients with established atherosclerotic disease, particularly after myocardial infarction.

The score counts nine clinical risk indicators. Each present indicator contributes one point. The composite outcome used in the post-MI development/validation work was cardiovascular death, recurrent myocardial infarction, or ischemic stroke.

Risk indicators and points

Risk indicatorCriterionPoints
Age≥75 years1
Congestive heart failureHistory of heart failure1
HypertensionHistory of hypertension1
Diabetes mellitusHistory of diabetes1
Prior strokeHistory of stroke1
Prior CABGHistory of coronary artery bypass grafting1
Peripheral arterial diseaseHistory of PAD1
Renal dysfunctionDocumented renal dysfunction1
Current smokingCurrent tobacco smoking1

Score interpretation

ScoreRisk stratum
0Low risk
1–2Intermediate risk
≥3High risk

These strata are presented as risk groupings, not as a patient-specific absolute event probability. Absolute event rates vary by cohort, follow-up duration, and endpoint definition.

Important use considerations

  • This is a secondary-prevention risk stratification instrument, not an acute MI diagnostic or in-hospital mortality score.
  • It does not estimate bleeding risk and should not be used alone to decide whether to extend dual antiplatelet therapy.
  • External validation studies report modest discrimination and variation in calibration across populations.

References

Mok Y, Ballew SH, Bash LD, et al. International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post-MI Patients. Journal of the American Heart Association. 2018;7(14):e008426. doi:10.1161/JAHA.117.008426
Williams BA, Chagin K, Bash LD, et al. External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarction. Atherosclerosis. 2018;272:80–86. doi:10.1016/j.atherosclerosis.2018.03.026
Zafrir B, Adawi S, Khalaily M, et al. Long-Term Risk Stratification of Patients Undergoing Coronary Angiography According to the Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention. Journal of the American Heart Association. 2019;8. Publisher record
Hashimoto T, Minami Y, Ako J, et al. Validation of the atherothrombotic risk score for secondary prevention in patients with acute myocardial infarction: the J-MINUET study. Heart and Vessels. 2021;36:1506–1513. doi:10.1007/s00380-021-01840-z
Clinical disclaimer: This calculator is intended for educational and clinical risk-stratification support. It does not replace clinical judgement, comprehensive assessment of recurrent ischemic and bleeding risks, or current guideline-directed secondary prevention. Confirm each input using the patient's clinical record. The score should not be used as the sole basis for treatment decisions.